Janssen Pharmaceutica Nv

Protagonist Therapeutics, Inc.

David C Polidori

Ashok Bhandari

Santhosh Francis Neelamkavil

Anne Fourie

Xiaoli Cheng

Tatiana Koudriakova

Nathalie Mertens

Shu Li

Felix Lai

Beverly Knight

Peter P Stein

Edward F Attiyeh

Kurtis E Bachman

Gopal Rajan

Douglas K Ways

Gary V Borzillo

Geraldine Broeckx

Mohammad Masjedizadeh

Gerald C Chu

Nishit Modi

Norman R Rosenthal

Paul Rothenberg

Dajun Sun

Giustino Di Pretoro

Disclosed herein are JAK inhibitors that have low systemic toxicity. In some aspects, the disclosure includes methods for treating disease states, disorders, and conditions mediated by JAK, such as stomacho-intestinal system cancers, including colorectal cancers and familial adenomatous polyposis.

Small molecule inhibitor of the JAK family of kinases

The present invention relates to compositions of peptide inhibitors of the interleukin-23 receptor (IL-23R) or pharmaceutically acceptable salt or solvate forms thereof, corresponding pharmaceutical compositions, methods and/or uses for treatment of autoimmune inflammation and related diseases and disorders.

Compositions of peptide inhibitors of Interleukin-23 receptor

The present invention is directed to the use of co-therapy comprising administration of canagliflozin and phentermine for the treatment of obesity and obesity related disorders. More particularly, the present invention is directed to co-therapy for treating obesity, for promoting weight loss and/or for suppressing appetite; for treating, delaying, slowing the progression of and/or preventing metabolic disorders (including for example Type 2 diabetes mellitus); for treating, delaying, slowing the progression of and/or preventing renal or fatty liver disorders (including for example NASH, NAFLD, etc.); for treating, delaying, slowing the progression of and/or preventing sleep disorders (including for example sleep apnea); for providing cardiovascular protection; for treating, delaying, slowing the progression of and/or preventing cardiovascular events (including major adverse cardiac events (MACE) such as myocardial infarction, unstable angina, cardiovascular death, revascularization, fatal or non-fatal cerebrovascular accident, peripheral arteriopathy, aortic events, hospitalization due to congestive heart failure, etc.); and/or for extending or prolonging life span.

Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders

Growing community of inventors

Rancho Sante Fe, CA, United States of America

David C Polidori